US 12,251,413 B2
Use of effective part extract of Monochasma savatieri in preparation of drug for treating inflammatory disease or tumor
Bin Mu, Harbin (CN); Jiangong Shi, Harbin (CN); Tiantai Zhang, Harbin (CN); Qinglan Guo, Harbin (CN); and Weiquan Li, Harbin (CN)
Assigned to HARBIN KANGLONG PHARMACEUTICAL CO., LTD, Heilongjiang Province (CN); and YICHUN BINGCHEN AGRICULTURAL TECHNOLOGY DEVELOPMENT CO., LTD., Jiangxi Province (CN)
Filed by Harbin Kanglong Pharmaceutical Co., Ltd., Harbin (CN); and Yichun Bingchen Ag. Tech. Dev. Co., Ltd., Yichun (CN)
Filed on Sep. 5, 2022, as Appl. No. 17/903,026.
Claims priority of application No. 202210673135.9 (CN), filed on Jun. 14, 2022.
Prior Publication US 2023/0398168 A1, Dec. 14, 2023
Int. Cl. A61K 36/64 (2006.01); A61P 1/00 (2006.01); A61P 17/06 (2006.01); A61P 19/02 (2006.01); A61P 29/00 (2006.01); A61P 31/00 (2006.01); A61P 35/00 (2006.01)
CPC A61K 36/64 (2013.01) [A61P 1/00 (2018.01); A61P 17/06 (2018.01); A61P 19/02 (2018.01); A61P 29/00 (2018.01); A61P 31/00 (2018.01); A61P 35/00 (2018.01); A61K 2236/331 (2013.01); A61K 2236/39 (2013.01)] 3 Claims
OG exemplary drawing
 
1. A method for treating an inflammatory disease, comprising contacting inflamed tissue with a drug comprising an effective amount of an effective part of Monochasma savatieri extract, wherein the effective part of Monochasma savatieri extract consists of fraction B2-13, fraction B2-15, fraction B2-16, and fraction B2-16-15;
wherein fraction B2-13, fraction B2-15, fraction B2-16, and fraction B2-16-15 are obtained by the following process:
(1) pulverizing Monochasma savatieri to obtain Monochasma savatieri powder, mixing the Monochasma savatieri powder with water, conducting extraction 2 to 4 times by decoction for 20 min to 40 min each time, combining filtrates, and conducting vacuum concentration on a combined filtrate to obtain the Monochasma savatieri crude extract; wherein water is added in a volume to mass ratio of 4 L water/1 kg of Monochasma savatieri powder; and extraction by decoction is conducted at about 100° C.;
(2) separating the Monochasma savatieri crude extract by an HP-20 macroporous resin column chromatography, and conducting elution with 150 L to 250 L of water and 150 L to 250 L of 40% to 60% ethanol in sequence, to obtain fraction LRCW-A and fraction LRCW-B, respectively;
(3) separating the fraction LRCW-B by an MCI column chromatography, and conducting elution with 35 L to 45 L of water, 35 L to 45 L of 25% to 35% ethanol, 35 L to 45 L of 40% to 60% ethanol, and 35 L to 45 L of 80% to 95% ethanol, to obtain fraction LRCW-B1, fraction LRCW-B2, fraction LRCW-B3, and fraction LRCW-B4, respectively;
(4) separating the fraction LRCW-B2 by a cross-linked dextrin gel LH-20 gel column chromatography, and conducting gradient elution with absolute ethanol and water in a volume ratio of 1:0 to 0:1 as a mobile phase; and combining same fractions having a same Rf value according to results of thin layer chromatography to obtain fraction B2-1, fraction B2-2, fraction B2-3, fraction B2-4, fraction B2-5, fraction B2-6, fraction B2-7, fraction B2-8, fraction B2-9, fraction B2-10, fraction B2-11, fraction B2-12, fraction B2-13, fraction B2-14, fraction B2-15, fraction B2-16, fraction B2-17, fraction B2-18, and fraction B2-19; and
(5) separating the fraction B2-16 by the cross-linked dextrin gel LH-20 gel column chromatography, and conducting gradient elution with absolute ethanol and water in a volume ratio of 1:0 to 0:1 as a mobile phase; and combining same fractions according to results of thin layer chromatography to obtain fraction B2-16-1, fraction B2-16-2, fraction B2-16-3, fraction B2-16-4, fraction B2-16-5, fraction B2-16-6, fraction B2-16-7, fraction B2-16-8, fraction B2-16-9, fraction B2-16-10, fraction B2-16-11, fraction B2-16-12, fraction B2-16-13, fraction B2-16-14, fraction B2-16-15, fraction B2-16-16, fraction B2-16-17, fraction B2-16-18, fraction B2-16-19, fraction B2-16-20, fraction B2-16-21, and fraction B2-16-22 wherein the inflammatory disease is caused by secretion of an inflammatory factor TNF-α.